Back to mobile site

uniQure (QURE) Reports Initial Topline Data from Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B

November 15, 2018 7:07 AM EST Send to a Friend
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login